A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.
By Dr. Sanchari Sinha Dutta, Ph.D.Sep 9 2024
GLP-1 receptor agonists are primarily used to treat type 2 diabetes by lowering blood sugar and reducing food intake. Glucagon-like peptide-1 receptor agonists are a class of drugs typically used to maintain glucose homeostasis in type 2 diabetes patients. These agonists also play a vital role in nerve cell differentiation and inhibition of neuroinflammation. Besides neuroprotective effects, GLP-1 receptor agonists have been found to be involved in brain networks associated with reward and addiction.
GLP-1 receptor agonists are widely expressed in the brain, playing a role in reward and addiction pathways. Regarding secondary outcomes, four out of five selected trials reported a significant reduction in body weight, BMI, and glycated hemoglobin levels in GLP-1 receptor agonist-treated participants.
Receptor Addiction Agonist Alcohol Alcohol Dependence Brain Glucagon Glucagon-Like Peptide-1 Glycated Hemoglobin Hemoglobin Mortality Nicotine Obesity Overdose Public Health Substance Use Disorder
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GLP-1 RA use linked to lower rates of hyperkalemia in type 2 diabetesTreatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor (RASi) discontinuation compared with treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) among patients with type 2 diabetes (T2D), according to a study published online...
Read more »
Q&A: Researcher discusses how GLP-1 weight loss drugs affect the liverDrugs such as Ozempic, Rybelsus and Wegovy have made news for their abilities to treat diabetes and encourage weight loss.
Read more »
GLP-1 therapy boosts visceral fat metabolism, driving weight lossResearchers discuss the role of enhanced visceral adipose tissue metabolism in mediating weight loss by glucagon-like peptide-1 drugs.
Read more »
Mouse study reveals new central action target of weight loss drug GLP-1R agonistsA research group led by Prof. Zhu Yingjie from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences has revealed the essential role of lateral septum (LS) neurons in mediating anorectic and weight-lowering effects of the anti-obesity drug, liraglutide, in mice.
Read more »
Q&A: Weighing the social costs of weight-loss drugsA wildly popular class of drugs called GLP-1 agonists—which includes Ozempic, Wegovy, Mounjaro, and Zepbound—are revolutionizing the treatment of obesity.
Read more »
Tirzepatide for type 2 diabetes associated with lower risks for mortality, adverse heart, kidney eventsFor patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated with lower risks for all-cause mortality and adverse cardiovascular and kidney events compared with glucagon-like peptide 1 receptor agonist treatment (GLP-1 RA), according...
Read more »